- |||||||||| Journal: Pharmacotherapeutic advances for chronic idiopathic constipation in adults. (Pubmed Central) - Nov 22, 2022
In addition, relamorelin, a ghrelin agonist, seems promising for accelerating colonic transit...On the other hand, the experience with these new agents is still limited, especially for long-term treatment. Another important point is that these new treatments for chronic idiopathic constipation are not available worldwide and their use could be somewhat limited by their still relatively high cost.
- |||||||||| Resolor (prucalopride) / J&J, Takeda, naronapride (ATI-7505) / Renexxion
Journal: Prokinetic actions of luminally acting 5-HT receptor agonists. (Pubmed Central) - Nov 21, 2021
Immunoreactivity for 5-HT R is present in the epithelial layer of the human small and large intestines. These findings demonstrated that stimulation of epithelial 5-HT Rs can potentiate propulsive motility and support the concept that mucosal 5-HT Rs could represent a safe and effective therapeutic target for the treatment of constipation.
- |||||||||| Retrospective data, Review, Journal: Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis. (Pubmed Central) - May 28, 2020
Prucalopride ranked first at 12 weeks, and many of the included trials recruited patients who previously did not respond to laxatives, suggesting that this drug is likely to be the most efficacious for patients with chronic idiopathic constipation. However, because treatment duration in most trials was 4-12 weeks, the long-term relative efficacy of these drugs is unknown.
|
